Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.61) by 18.03 percent. This is a 13.64 percent decrease over losses of $(0.44) per share from the same period last year.
SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $27
SVB Leerink analyst Daina Graybosch maintains Century Therapeutics (NASDAQ:IPSC) with a Outperform and lowers the price target from $32 to $27.
